A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Evolus, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 58,046 shares of EOLS stock, worth $643,149. This represents 0.0% of its overall portfolio holdings.

Number of Shares
58,046
Holding current value
$643,149
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$10.66 - $17.48 $618,770 - $1.01 Million
58,046 New
58,046 $940,000
Q1 2024

May 09, 2024

BUY
$9.99 - $14.91 $309,580 - $462,045
30,989 New
30,989 $433,000

Others Institutions Holding EOLS

About Evolus, Inc.


  • Ticker EOLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 56,094,800
  • Market Cap $622M
  • Description
  • Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...
More about EOLS
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.